Eli Lilly has launched Alzheimer's drug Lormalzi in India, the country's first approved amyloid plaque-targeting therapy for early-stage patients. While the drug aims to slow cognitive decline by removing amyloid buildup in the brain, experts remain divided over its real-world benefits. The launch highlights India's rising dementia burden and growing demand for advanced Alzheimer's treatments.